Sartorius Stedim Biotech Acquires kSep Systems
The company acquired kSep Holdings, a single-use bioprocessing solutions company.
Sartorius Stedim Biotech (SSB) announced on July 6, 2016 that it will acquire kSep Holdings, a single-use bioprocessing solutions company based in Morrisville, North Carolina. The transaction valued kSep at approximately $28 million and will be closed by the end of July 2016. kSep markets single-use, fully automated centrifugation systems used for manufacturing biopharmaceuticals, such as vaccines, cell-based therapeutics, and monoclonal antibodies. kSep Systems is a spinoff from KBI Biopharma and was established in 2011.
Source: Sartorius Stedim Biotech
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.
